Slides

Acromegaly Highlights from ENDO 2021 - slides

References

Arshad MF, Ogunleye O. Medical Treatment Achieves Similar Quality of Life to Surgically Treated Acromegaly Patients in Remission: The QuaLAT Study. J Endo Soc 2021; 5(suppl 1): A522.

Biermasz N, Fleseriu M, Dreval AV et al. Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands—Results From the MPOWERED Trial. J Endo Soc 2021; 5(suppl 1): A522-A523.

Freda P, Fleseriu M, Dreval AV et al. Safety Results From MPOWERED, a Phase 3 Trial of Oral Octreotide Capsules in Adults With Acromegaly. J Endo Soc 2021; 5(suppl 1): A527-A528.

Gordon MB, Fleseriu M, Dreval AV et al. Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the
MPOWERED Trial. J Endo Soc 2021; 5(suppl 1): A520-A521.

Fleseriu M, Dreval AV, Yulia Pokramovich Y et al. A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands. J Endo Soc 2021; 5(suppl 1): A5217.

Samson SL, Nachtigall LB, Fleseriu M. One-Year Outcomes of the Open-Label Extension of CHIASMA OPTIMAL, a Phase 3 Study of Oral Octreotide Capsules in Acromegaly. J Endo Soc
2021; 5(suppl 1): A515-A516.

Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy

Fleseriu M, Dreval AV, Yulia Pokramovich Y et al J Endo Soc 2021; 5(suppl 1): A518-A519.

Gadelha MR, Gordon, MB, Doknic M, et al. Safety and Efficacy of Switching Injected Peptide Long-Acting Somatostatin Receptor Ligands to Once Daily Oral Paltusotine: ACROBAT Edge Phase 2 Study. J Endo Soc 2021; 5(suppl 1): A526-A527.

Luo R, Burke G, Mui C et al .Pharmacokinetics and Safety of an Improved Oral Formulation of Paltusotine, a Selective, Non-Peptide Somatostatin Receptor 2 (SST2) Agonist for the Treatment of Acromegaly. J Endo Soc 2021; 5(suppl 1): A524.

Hordejuk D, Laws ER, Kaiser UB. Pegvisomant as Monotherapy or Combination Therapy in Somatostatin Refractory Acromegaly. J Endo Soc 2021; 5(suppl 1): A523-A524.

Fleseriu M, Barkan A, del Pilar Schneider M et al. The Pharmacological Burden of Comorbidities in Acromegaly. J Endo Soc 2021; 5(suppl 1): A649-A650.

Petersenn S, Houchard A, del Pilar Schneider M, et al. Use of Oral Concomitant Medications in Patients With Acromegaly. J Endo Soc 2021; 5(suppl 1): A528-A529.

Khan SA, Ram N, Masood MQ. Prevalence of Abnormal Glucose Metabolism in Acromegaly & Impact of Treatment Modalities on Glucose Metabolism. J Endo Soc 2021; 5(suppl 1): A647-A648.

Vinueza DFP MD1, del Socorro G-P, Solis-Pazmino AP. Assessment of the Severity of Carpal Tunnel Syndrome in Patients With Acromegaly: A Focus on Clinical, Biochemical and Image Outcomes. J Endo Soc 2021; 5(suppl 1): A648.

Firlatan B, Sendur SN, MD, Oguz SH et al The Secret Behind Anemia in Patients With Acromegaly. J Endo Soc 2021; 5(suppl 1): A650.

Jointly Provided by American Academy of CME and CheckRare CE

Supported by an educational grant from Ipsen Biopharmaceuticals, Inc.

Start date: June 16, 2021
End date: June 30, 2022
NO LONGER AVAILABLE FOR CREDIT
Estimated time to complete: 0.25 hours

Activity Description

This CME activity highlights the latest research about Acromegaly that was presented at ENDO 2021, the annual meeting of the Endocrine Society. This activity provides expert analysis on that research and its clinical relevance for busy members of the care team in order to help them care for patients with acromegaly.

Activity Faculty

Maria Fleseriu, MD, FACE
Professor of Medicine, Division of Endocrinology, Diabetes and Clinical Nutrition,
Professor of Neurological Surgery, School of Medicine
Director of Pituitary Center
Oregon Health & Science University
Portland, Oregon

Target Audience

This activity has been designed to meet the educational needs of physicians caring for individuals with Acromegaly. Other members of the care team may also participate.

After participating in the activity, learners should be better able to:

• Describe the latest research being presented to better manage acromegaly and its clinical relevance

Accreditation and Credit Designation

In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and CheckRare CE. American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

American Academy of CME, Inc., designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement

According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.

Disclosures are as follows:

Dr. Fleseriu discloses the following financial relationships:
Scientific Consultant: Chiasma, Crinetics, Ipsen, Recordati, Pfizer
Grant/Research Support: Chiasma, Crinetics, Ionis, Novartis, Recordati

Planners for this activity have no relevant financial relationships with any commercial interests.

This activity will review off-label or investigational information.

The opinions expressed in this educational activity are those of the faculty, and do not represent those of the Academy or CheckRare CE. This activity is intended as a supplement to existing knowledge, published information, and practice guidelines. Learners should appraise the information presented critically, and draw conclusions only after careful consideration of all available scientific information.

Method of Participation

There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CME credit for your participation, please complete the post-program assessment. Your certificate can be mailed to you in approximately 30 days.

Hardware/Software Requirements

Windows Requirements: • Operating system: Windows XP Service Pack 2 or later • Browser: Internet Explorer 7 or later, Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection

Macintosh Requirements: • Operating system: Mac OS X v10.3 or later • Browser: Mozilla Firefox 2.5 or later • Internet connection: DSL, cable modem, or other high-speed connection

Privacy

For more information about the American Academy of CME privacy policy, please access http://www.academycme.org/privacy.htm. For more information about CheckRare's privacy policy, please access https://checkrare.com/privacy/

Contact

For any questions, please contact: [email protected]

Copyright

© 2021. This CME-certified activity is held as copyrighted © by American Academy of CME and CheckRare CE. Through this notice, the Academy and CheckRare grant permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).

Transcripts

Acromegaly Highlights from ENDO 2021 - transcripts